Tumor efficacy and bone marrow-sparing properties of TER286, a cytotoxin activated by glutathione S-transferase. 1998

A S Morgan, and P E Sanderson, and R F Borch, and K D Tew, and Y Niitsu, and T Takayama, and D D Von Hoff, and E Izbicka, and G Mangold, and C Paul, and U Broberg, and B Mannervik, and W D Henner, and L M Kauvar
Terrapin Technologies, Inc., South San Francisco, California 94080, USA.

TER286 is a latent drug activated by human glutathione S-transferase (GST) isoforms P1-1 and A1-1 to produce a nitrogen mustard alkylating agent. M7609 human colon carcinoma, selected for resistance to doxorubicin, and MCF-7 human breast carcinoma, selected for resistance to cyclophosphamide, both showed increased sensitivity to TER286 over their parental lines in parallel with increased expression of GST P1-1. In primary human tumor clonogenic assays, the spectrum of cytotoxic activity observed for TER286 was both broad and unusual when compared to a variety of current drugs. In murine xenografts of M7609 engineered to have high, medium, or low GST P1-1, responses to TER286 were positively correlated with the level of P1-1. Cytotoxicity was also observed in several other cell culture and xenograft models. In xenografts of the MX-1 human breast carcinoma, tumor growth inhibition or regression was observed in nearly all of the animals treated with an aggressive regimen of five daily doses. This schedule resulted in a 24-h posttreatment decline in bone marrow progenitors to 60% of control and was no worse than for a single dose of TER286. These studies have motivated election of TER286 as a clinical candidate.

UI MeSH Term Description Entries
D008819 Mice, Nude Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses. Athymic Mice,Mice, Athymic,Nude Mice,Mouse, Athymic,Mouse, Nude,Athymic Mouse,Nude Mouse
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D011355 Prodrugs A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug. Drug Precursor,Drug Precursors,Pro-Drug,Prodrug,Pro-Drugs,Precursor, Drug,Precursors, Drug,Pro Drug,Pro Drugs
D003603 Cytotoxins Substances that are toxic to cells; they may be involved in immunity or may be contained in venoms. These are distinguished from CYTOSTATIC AGENTS in degree of effect. Some of them are used as CYTOTOXIC ANTIBIOTICS. The mechanism of action of many of these are as ALKYLATING AGENTS or MITOSIS MODULATORS. Cytolysins,Cytotoxic Agent,Cytotoxic Agents,Cytotoxin,Agent, Cytotoxic
D005978 Glutathione A tripeptide with many roles in cells. It conjugates to drugs to make them more soluble for excretion, is a cofactor for some enzymes, is involved in protein disulfide bond rearrangement and reduces peroxides. Reduced Glutathione,gamma-L-Glu-L-Cys-Gly,gamma-L-Glutamyl-L-Cysteinylglycine,Glutathione, Reduced,gamma L Glu L Cys Gly,gamma L Glutamyl L Cysteinylglycine
D005982 Glutathione Transferase A transferase that catalyzes the addition of aliphatic, aromatic, or heterocyclic FREE RADICALS as well as EPOXIDES and arene oxides to GLUTATHIONE. Addition takes place at the SULFUR. It also catalyzes the reduction of polyol nitrate by glutathione to polyol and nitrite. Glutathione S-Alkyltransferase,Glutathione S-Aryltransferase,Glutathione S-Epoxidetransferase,Ligandins,S-Hydroxyalkyl Glutathione Lyase,Glutathione Organic Nitrate Ester Reductase,Glutathione S-Transferase,Glutathione S-Transferase 3,Glutathione S-Transferase A,Glutathione S-Transferase B,Glutathione S-Transferase C,Glutathione S-Transferase III,Glutathione S-Transferase P,Glutathione Transferase E,Glutathione Transferase mu,Glutathione Transferases,Heme Transfer Protein,Ligandin,Yb-Glutathione-S-Transferase,Glutathione Lyase, S-Hydroxyalkyl,Glutathione S Alkyltransferase,Glutathione S Aryltransferase,Glutathione S Epoxidetransferase,Glutathione S Transferase,Glutathione S Transferase 3,Glutathione S Transferase A,Glutathione S Transferase B,Glutathione S Transferase C,Glutathione S Transferase III,Glutathione S Transferase P,Lyase, S-Hydroxyalkyl Glutathione,P, Glutathione S-Transferase,Protein, Heme Transfer,S Hydroxyalkyl Glutathione Lyase,S-Alkyltransferase, Glutathione,S-Aryltransferase, Glutathione,S-Epoxidetransferase, Glutathione,S-Transferase 3, Glutathione,S-Transferase A, Glutathione,S-Transferase B, Glutathione,S-Transferase C, Glutathione,S-Transferase III, Glutathione,S-Transferase P, Glutathione,S-Transferase, Glutathione,Transfer Protein, Heme,Transferase E, Glutathione,Transferase mu, Glutathione,Transferase, Glutathione,Transferases, Glutathione
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013370 Subrenal Capsule Assay In vivo method of screening investigative anticancer drugs and biologic response modifiers for individual cancer patients. Fresh tumor tissue is implanted under the kidney capsule of immunocompetent mice or rats; gross and histological assessments follow several days after tumor treatment in situ. Subrenal Capsule Xenograft Assay,Assay, Subrenal Capsule,Assays, Subrenal Capsule,Subrenal Capsule Assays
D014407 Tumor Cells, Cultured Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely. Cultured Tumor Cells,Neoplastic Cells, Cultured,Cultured Neoplastic Cells,Cell, Cultured Neoplastic,Cell, Cultured Tumor,Cells, Cultured Neoplastic,Cells, Cultured Tumor,Cultured Neoplastic Cell,Cultured Tumor Cell,Neoplastic Cell, Cultured,Tumor Cell, Cultured

Related Publications

A S Morgan, and P E Sanderson, and R F Borch, and K D Tew, and Y Niitsu, and T Takayama, and D D Von Hoff, and E Izbicka, and G Mangold, and C Paul, and U Broberg, and B Mannervik, and W D Henner, and L M Kauvar
May 1994, Journal of clinical pathology,
A S Morgan, and P E Sanderson, and R F Borch, and K D Tew, and Y Niitsu, and T Takayama, and D D Von Hoff, and E Izbicka, and G Mangold, and C Paul, and U Broberg, and B Mannervik, and W D Henner, and L M Kauvar
January 2011, Asian Pacific journal of cancer prevention : APJCP,
A S Morgan, and P E Sanderson, and R F Borch, and K D Tew, and Y Niitsu, and T Takayama, and D D Von Hoff, and E Izbicka, and G Mangold, and C Paul, and U Broberg, and B Mannervik, and W D Henner, and L M Kauvar
January 2014, PloS one,
A S Morgan, and P E Sanderson, and R F Borch, and K D Tew, and Y Niitsu, and T Takayama, and D D Von Hoff, and E Izbicka, and G Mangold, and C Paul, and U Broberg, and B Mannervik, and W D Henner, and L M Kauvar
January 2015, PloS one,
A S Morgan, and P E Sanderson, and R F Borch, and K D Tew, and Y Niitsu, and T Takayama, and D D Von Hoff, and E Izbicka, and G Mangold, and C Paul, and U Broberg, and B Mannervik, and W D Henner, and L M Kauvar
August 2005, Expert opinion on investigational drugs,
A S Morgan, and P E Sanderson, and R F Borch, and K D Tew, and Y Niitsu, and T Takayama, and D D Von Hoff, and E Izbicka, and G Mangold, and C Paul, and U Broberg, and B Mannervik, and W D Henner, and L M Kauvar
May 2004, Molecular pharmacology,
A S Morgan, and P E Sanderson, and R F Borch, and K D Tew, and Y Niitsu, and T Takayama, and D D Von Hoff, and E Izbicka, and G Mangold, and C Paul, and U Broberg, and B Mannervik, and W D Henner, and L M Kauvar
October 2002, Molecular cancer therapeutics,
A S Morgan, and P E Sanderson, and R F Borch, and K D Tew, and Y Niitsu, and T Takayama, and D D Von Hoff, and E Izbicka, and G Mangold, and C Paul, and U Broberg, and B Mannervik, and W D Henner, and L M Kauvar
January 1991, Biomedical science,
A S Morgan, and P E Sanderson, and R F Borch, and K D Tew, and Y Niitsu, and T Takayama, and D D Von Hoff, and E Izbicka, and G Mangold, and C Paul, and U Broberg, and B Mannervik, and W D Henner, and L M Kauvar
December 1980, Archives of biochemistry and biophysics,
A S Morgan, and P E Sanderson, and R F Borch, and K D Tew, and Y Niitsu, and T Takayama, and D D Von Hoff, and E Izbicka, and G Mangold, and C Paul, and U Broberg, and B Mannervik, and W D Henner, and L M Kauvar
December 1997, Rinsho byori. The Japanese journal of clinical pathology,
Copied contents to your clipboard!